Apisyn Healthcare is an API manufacturer based in India. It holds 6 active US drug master files across a filed portfolio of 5 molecules. Customs aggregates show $1.4M of exports covering 17 molecules to 2 destinations in 2025.
| Site | FDA FEI |
|---|---|
| Ahmedabad, India | 3035217826 |
| Molecule | Regulators | Docs |
|---|---|---|
| Linezolid | US FDA | 2 |
| Apixaban | US FDA | 1 |
| Methimazole | US FDA | 1 |
| Rivaroxaban | US FDA | 1 |
| Sotalol | US FDA | 1 |
Also appears on these molecule pages
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2025 | Not reported | $1.4M | 2 |
| 2024 | Not reported | $43K | 1 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.
Choose your molecules and target markets. Apisyn Healthcare comes back tiered against every other supplier able to file there.
Start for freeRanked by shared active ingredients where we have them, otherwise by country and comparable credentials.